Deloitte has acquired the assets of Intrasphere Technologies, Inc., a global drug safety and regulatory consulting business. Intrasphere, headquartered in Jersey City, NJ, with European headquarters in London, provides professional services to help life sciences companies improve product safety, signal intelligence, pharmacovigilance and regulatory information management capabilities. Terms of the acquisition were not disclosed.

The acquisition includes Intrasphere’s PharmaCM software that enables life sciences companies to register clinical trial information on government-mandated registries through workflow-enabled functionality that allows for content management and re-use. The PharmaCM product will be provided as a service offering within Deloitte Managed Analytics, which is led by Richard Cohen, principal, Deloitte Consulting LLP. This new business adds to Deloitte’s enterprise risk, security and regulatory compliance services, and additional business advisory services.

“We are excited about this important and strategic investment,” said Dan Ressler, principal, Deloitte Consulting LLP, who will lead Deloitte’s new drug safety and regulatory consulting business as part of his overall responsibilities in leading research and development informatics in life sciences. “The growing impact of health information technology and social media, greater complexity of therapeutic offerings in the marketplace, and an increasingly complex and stringent regulatory environment, in particular, have created an impetus for more proactive product safety and regulatory support services.”

“Deloitte’s broad-based relationships in life sciences give us access to clients where we don’t have a presence today. Moreover, our staff and leadership now have the opportunity to gain exposure to a variety of resources and opportunities as part of Deloitte,” said Bill Karl, co-founder and former chief executive officer of Intrasphere. Karl now joins Deloitte Consulting LLP as a director.